[1]
|
沈海燕. 肾性贫血机制和治疗的研究进展[J]. 现代医药卫生, 2022, 38(1): 81-85.
|
[2]
|
Eriksson, D., Goldsmith, D., Teitsson, S., Jackson, J. and van Nooten, F. (2016) Cross-Sectional Survey in CKD Patients across Europe Describing the Association between Quality of Life and Anaemia. BMC Nephrology, 17, Article No. 97. https://doi.org/10.1186/s12882-016-0312-9
|
[3]
|
董建华, 范文静, 吴边, 黄力, 李川, 樊蓉, 葛永纯. 罗沙司他治疗血液透析患者红细胞生成素低反应性贫血的疗效观察[J]. 肾脏病与透析肾移植杂志, 2021, 30(3): 211-216.
|
[4]
|
Koulouridis, I., Alfayez, M., Trikalinos, T.A., Balk, E.M. and Jaber, B.L. (2013) Dose of Erythropoie-sis-Stimulating Agents and Adverse Outcomes in CKD: A Metaregression Analysis. American Journal of Kidney Dis-eases the Official Journal of the National Kidney Foundation, 61, 44-56. https://doi.org/10.1053/j.ajkd.2012.07.014
|
[5]
|
王培培, 吴涛. 口服罗沙司他对慢性肾脏病并肾性贫血的治疗效果观察[J]. 山东医药, 2020, 60(33): 73-75.
|
[6]
|
司倩楠, 建刚, 刘新宇. 维持性血液透析患者微炎症状态与铁缺乏的相关性分析[J]. 山东医药, 2020, 60(2): 69-71.
|
[7]
|
Babitt, J.L. and Lin, H.Y. (2012) Mechanisms of Anemia in CKD. Journal of the American Society of Nephrology, 23, 1631-1634. https://doi.org/10.1681/ASN.2011111078
|
[8]
|
Fishbane, S. and Spinowitz, B. (2018) Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018. American Journal of Kidney Diseases, 71, 423-435. https://doi.org/10.1053/j.ajkd.2017.09.026
|
[9]
|
Maxwell, P.H., Osmond, M.K., Pugh, C.W., Heryet, A., Nicholls, L.G., Tan, C.C., Doe, B.G., Ferguson, D., Johnson, M.H. and Ratcliffe, P.J. (1993) Identification of the Renal Erythro-poietin-Producing Cells Using Transgenic Mice. Kidney International, 44, 1149-1162. https://doi.org/10.1038/ki.1993.362
|
[10]
|
Semenza, G.L., Koury, S.T., Nejfelt, M.K., Gearhart, J.D. and Anto-narakis, S.E. (1991) Cell-Type-Specific and Hypoxia-Inducible Expression of the Human Erythropoietin Gene in Trans-genic Mice. Proceedings of the National Academy of Sciences of the United States of America, 88, 8725-8729. https://doi.org/10.1073/pnas.88.19.8725
|
[11]
|
Kaplan, J.M., Sharma, N. and Dikdan, S. (2018) Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease. International Journal of Molecular Sci-ences, 19, Article No. 389.
https://doi.org/10.3390/ijms19020389
|
[12]
|
Kaelin Jr., W.G. and Ratcliffe, P.J. (2008) Oxygen Sensing by Meta-zoans: The Central Role of the HIF Hydroxylase Pathway. Molecular Cell, 30, 393-402. https://doi.org/10.1016/j.molcel.2008.04.009
|
[13]
|
Schödel, J., Oikonomopoulos, S., Ragoussis, J., Pugh, C.W., Ratcliffe, P.J. and Mole, D.R. (2011) High-Resolution Genome-Wide Mapping of HIF-Binding Sites by ChIP-Seq. Blood, 117, e207-e217.
https://doi.org/10.1182/blood-2010-10-314427
|
[14]
|
Luo, X., Hill, M., Johnson, A. and Latunde-Dada, G.O. (2014) Modulation of Dcytb (Cybrd 1) Expression and Function by Iron, Dehydroascorbate and Hif-2α in Cultured Cells. Bio-chimica et Biophysica Acta (BBA), 1840, 106-112.
|
[15]
|
Mastrogiannaki, M., Matak, P., Keith, B., Simon, M.C. and Peyssonnaux, C. (2009) HIF-2α, but Not HIF-1α, Promotes Iron Absorption in Mice. Journal of Clinical Investigation, 119, 1159-1166. https://doi.org/10.1172/JCI38499
|
[16]
|
Provenzano, R., Besarab, A., Sun, C.H., Diamond, S.A., Durham, J.H., Cangiano, J.L., Aiello, J.R., Novak, J.E., Lee, T. and Leong, R. (2016) Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD. Clinical Journal of the American Society of Nephrology, 11, 982-991.
https://doi.org/10.2215/CJN.06890615
|
[17]
|
Pergola, P.E., Spinowitz, B.S., Hartman, C.S., Maroni, B.J. and Haase, V.H. (2016) Vadadustat, a Novel Oral HIF Stabilizer, Provides Effective Anemia Treatment in Nondialy-sis-Dependent Chronic Kidney Disease. Kidney International, 90, 1115-1122. https://doi.org/10.1016/j.kint.2016.07.019
|
[18]
|
Semenza, G.L. (2014) Oxygen Sensing, Hypoxia-Inducible Factors, and Disease Pathophysiology. Annual Review of Pathology: Mechanisms of Disease, 9, 47-71. https://doi.org/10.1146/annurev-pathol-012513-104720
|
[19]
|
Choudhry, H. and Harris, A.L. (2018) Advances in Hypoxia-Inducible Factor Biology. Cell Metabolism, 27, 281-298.
https://doi.org/10.1016/j.cmet.2017.10.005
|
[20]
|
Heidbreder, M., Frohlich, F., Johren, O., Dendorfer, A., Qadri, F. and Dominiak, P. (2003) Hypoxia Rapidly Activates HIF-3α mRNA Expression. The FASEB Journal, 17, 1541-1543. https://doi.org/10.1096/fj.02-0963fje
|
[21]
|
Fong, G.H. and Takeda, K. (2008) Role and Regulation of Prolyl Hy-droxylase Domain Proteins. Cell Death and Differentiation, 15, 635-641. https://doi.org/10.1038/cdd.2008.10
|
[22]
|
Liu, Q.D., Davidoff, O., Niss, K. and Haase, V.H. (2012) Hypox-ia-Inducible Factor Regulates Hepcidin via Erythropoietin-Induced Erythropoiesis. Journal of Clinical Investigation, 122, 4635-4644. https://doi.org/10.1172/JCI63924
|
[23]
|
Drevytska, T., Gavenauskas, B., Drozdovska, S., et al. (2012) HIF-3α mRNA Expression Changes in Different Tissues and Their Role in Adaptation to Intermittent Hypoxia and Physical Exercise. Pathophysiology, 19, 205-214.
https://doi.org/10.1016/j.pathophys.2012.06.002
|
[24]
|
Provenzano, R., Besarab, A., Wright, S., Dua, S., Zeig, S., Nguyen, P., Poole, L., Saikali, K.G., Saha, G. and Hemmerich, S. (2016) Roxadustat (FG-4592) versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Ac-tive-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study. American Journal of Kidney Diseases: The Of-ficial Journal of the National Kidney Foundation, 67, 912-924.
https://doi.org/10.1053/j.ajkd.2015.12.020
|
[25]
|
Yeh, T.L., Leissing, T.M., Abboud, M.I., Thinnes, C.C., Atasoylu, O., Holt-Martyn, J.P., Zhang, D., Tumber, A., Lippl, K. and Lohans, C.T. (2017) Molecular and Cellular Mechanisms of HIF Prolyl Hydroxylase Inhibitors in Clinical Trials. Chemical Science, 8, 7651-7688. https://doi.org/10.1039/C7SC02103H
|
[26]
|
Bernhardt, W.M., Wiesener, M.S., Scigalla, P., Chou, J., Schmieder, R.E., Gunzler, V. and Eckardt, K.U. (2010) Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD. Journal of the American Society of Nephrology, 21, 2151-2156. https://doi.org/10.1681/ASN.2010010116
|
[27]
|
Akizawa, T., Otsuka, T., Reusch, M. and Ueno, M. (2019) Inter-mittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study. Therapeutic Apheresis and Dialysis, 24, 115-125. https://doi.org/10.1111/1744-9987.12888
|
[28]
|
Gupta, N. and Wish, J.B. (2017) Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients with CKD. American Journal of Kidney Dis-eases, 69, 815-826.
https://doi.org/10.1053/j.ajkd.2016.12.011
|
[29]
|
Chen, N., Hao, C., Peng, X., Lin, H. and Yu, K. (2019) Roxadu-stat for Anemia in Patients with Kidney Disease Not Receiving Dialysis. New England Journal of Medicine, 381, 1001-1010. https://doi.org/10.1056/NEJMoa1813599
|
[30]
|
陈楠. 罗沙司他在慢性肾脏病患者肾性贫血治疗中的应用[J]. 中华内科杂志, 2019, 58(12): 919-920.
|
[31]
|
陈豫闽, 刘俊英, 贾国强, 郭志玲. 罗沙司他在维持性腹膜透析患者肾性贫血治疗中的应用效果[J]. 广东医学, 2021, 42(2): 216-220. https://doi.org/10.13820/j.cnki.gdyx.20202986
|
[32]
|
程红娟, 魏芝薇, 史慧, 李桂珍, 吴晓蓉. 罗沙司他治疗维持性血液透析患者难治性肾性贫血的疗效观察[J]. 实用临床医药杂志, 2021, 25(14): 75-77+83.
|
[33]
|
谷茜, 景三辉, 吴歌. 罗沙司他口服治疗肾性贫血效果观察[J]. 山东医药, 2022, 62(12): 60-63.
|